Carisma Therapeutics Inc. (CARM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenues | - | 3,729 | 3,385 | 9,197 |
| Research and development | 2,424 | 9,156 | 11,326 | 15,307 |
| General and administrative | 3,354 | 3,907 | 5,203 | 5,560 |
| Total operating expenses | 5,778 | 13,063 | 16,529 | 20,867 |
| Operating loss | -5,778 | -9,334 | -13,144 | -11,670 |
| Loss on sale of held for sale assets | -3,539 | - | - | - |
| Loss on abandonment of operating lease right-of-use asset | 927 | - | - | - |
| Other income, net | 470 | - | - | - |
| Interest income, net | - | 68 | 442 | 508 |
| Pre-tax loss | -9,774 | -9,266 | -12,702 | -11,162 |
| Income tax expense | - | - | - | - |
| Net loss | -9,774 | -9,266 | -12,702 | -11,162 |
| Comprehensive loss | - | - | -12,702 | -11,162 |
| Net loss per share of common stock, basic (in usd per share) | -0.23 | -0.22 | -0.31 | -0.27 |
| Net loss per share of common stock, diluted (in usd per share) | -0.23 | -0.22 | -0.31 | -0.27 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 41,788,096 | 41,771,213 | 41,588,035,000 | 41,543,553 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 41,788,096 | 41,771,213 | 41,588,035,000 | 41,543,553 |